Advertisement
Advertisement
U.S. Markets open in 3 hrs 19 mins
Advertisement
Advertisement
Advertisement
Advertisement

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4741+0.0516 (+12.21%)
At close: 04:00PM EDT
0.4800 +0.01 (+1.24%)
Pre-Market: 05:30AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4225
Open0.4300
Bid0.0000 x 1800
Ask0.0000 x 1100
Day's Range0.4200 - 0.4800
52 Week Range0.4100 - 5.6900
Volume1,156,920
Avg. Volume593,073
Market Cap59.499M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.31
  • GlobeNewswire

    Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

    Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO

  • GlobeNewswire

    Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

    BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting

  • GlobeNewswire

    Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

    BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (

Advertisement
Advertisement